Combined treatment with naringin and osthole ameliorates colitis through microbiota-amino acid metabolism and the JNK pathway

doi:10.1007/s13659-025-00582-z

Abstract

Abstract: Inflammatory bowel disease (IBD), particularly ulcerative colitis, involves disruption of the intestinal mucosal barrier due to ecological and metabolic imbalances in the gut as its underlying pathology. Current therapies for Ulcerative colitis (UC) exhibit limited efficacy and adverse effects, necessitating the development of novel treatment strategies. Naringin and osthole are natural herbal compounds that show therapeutic potential in various inflammatory models due to their excellent anti-inflammatory activity. However, their combined therapeutic effects and precise mechanisms in UC remain unreported. This study aimed to explore the therapeutic effectiveness and mechanism of naringin combined with osthole in addressing dextran sodium sulfate (DSS)-induced colitis. The investigation centered on their impact on the disruption of the intestinal epithelial cell barrier, modulation of intestinal flora composition, alteration of metabolites, and inflammation model in vitro. Modal assessment encompassed body weight, disease activity index (DAI) score, colon length, and histopathological examination. Intestinal barrier integrity was evaluated through Quantitative Real-Time PCR, western blotting, and immunofluorescence staining. Microbiota abundance and metabolic levels were assessed using 16S ribosomal RNA gene sequencing and metabolomics analysis. Protein expression levels of pertinent pathways and associated receptors were tested through network pharmacology prediction and western blot analysis. Naringin and osthole synergistically relieved colitis symptoms in mice compared with either drug alone or 5-aminosalicylic acid, as evidenced by weight loss recovery, DAI scores, and colon length preservation. Mechanistically, naringin combined with osthole down-regulated the expression level of JNK/NF-κB signaling pathway related proteins and repaired intestinal barrier. Furthermore, the combination regulates the composition of the microflora and promotes the restoration of a steady state of the microflora. Metabolomic revealed amino acid-tryptophan metabolism as a key metabolic pathway. It also reveals the microbiota-tryptophan pathway as a potential therapeutic strategy. Naringin combined with osthole can alleviate DSS-induced colitis more effectively by JNK/NF-κB signaling pathway, repairing barrier function and regulating intestinal microbiota and metabolites. These findings provide a theoretical basis for the combination therapy strategy to enhance the efficacy of potential functional food in treating ulcerative colitis.

Key words: Naringin, Osthole, Intestinal barrier, Ulcerative colitis, Gut microbiota, Amino acid metabolism

摘要： Inflammatory bowel disease (IBD), particularly ulcerative colitis, involves disruption of the intestinal mucosal barrier due to ecological and metabolic imbalances in the gut as its underlying pathology. Current therapies for Ulcerative colitis (UC) exhibit limited efficacy and adverse effects, necessitating the development of novel treatment strategies. Naringin and osthole are natural herbal compounds that show therapeutic potential in various inflammatory models due to their excellent anti-inflammatory activity. However, their combined therapeutic effects and precise mechanisms in UC remain unreported. This study aimed to explore the therapeutic effectiveness and mechanism of naringin combined with osthole in addressing dextran sodium sulfate (DSS)-induced colitis. The investigation centered on their impact on the disruption of the intestinal epithelial cell barrier, modulation of intestinal flora composition, alteration of metabolites, and inflammation model in vitro. Modal assessment encompassed body weight, disease activity index (DAI) score, colon length, and histopathological examination. Intestinal barrier integrity was evaluated through Quantitative Real-Time PCR, western blotting, and immunofluorescence staining. Microbiota abundance and metabolic levels were assessed using 16S ribosomal RNA gene sequencing and metabolomics analysis. Protein expression levels of pertinent pathways and associated receptors were tested through network pharmacology prediction and western blot analysis. Naringin and osthole synergistically relieved colitis symptoms in mice compared with either drug alone or 5-aminosalicylic acid, as evidenced by weight loss recovery, DAI scores, and colon length preservation. Mechanistically, naringin combined with osthole down-regulated the expression level of JNK/NF-κB signaling pathway related proteins and repaired intestinal barrier. Furthermore, the combination regulates the composition of the microflora and promotes the restoration of a steady state of the microflora. Metabolomic revealed amino acid-tryptophan metabolism as a key metabolic pathway. It also reveals the microbiota-tryptophan pathway as a potential therapeutic strategy. Naringin combined with osthole can alleviate DSS-induced colitis more effectively by JNK/NF-κB signaling pathway, repairing barrier function and regulating intestinal microbiota and metabolites. These findings provide a theoretical basis for the combination therapy strategy to enhance the efficacy of potential functional food in treating ulcerative colitis.

关键词: Naringin, Osthole, Intestinal barrier, Ulcerative colitis, Gut microbiota, Amino acid metabolism

Mengqin Chen, Zihao Lu, Tong Zhang, Guoping Li, Qingyu Zheng, Tao Zhang. Combined treatment with naringin and osthole ameliorates colitis through microbiota-amino acid metabolism and the JNK pathway[J]. Natural Products and Bioprospecting, 2026, 16(3): 31-31.

References

[1] Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet (London, England). 2012;380:1606-19. https://doi.org/10.1016/s0140-6736(12)60150-0.
[2] Na YR, Stakenborg M, Seok SH, Matteoli G. Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD. Nat Rev Gastroenterol Hepatol. 2019;16:531-43. https://doi.org/10.1038/s41575-019-0172-4.
[3] Chung CH, Jung W, Keum H, Kim TW, Jon S. Nanoparticles derived from the natural antioxidant rosmarinic acid ameliorate acute inflammatory bowel disease. ACS Nano. 2020;14:6887-96. https://doi.org/10.1021/acsnano.0c01018.
[4] Torres J, Danese S, Colombel JF. New therapeutic avenues in ulcerative colitis: thinking out of the box. Gut. 2013;62:1642-52. https://doi.org/10.1136/gutjnl-2012-303959.
[5] Glassner KL, Abraham BP, Quigley EMM. The microbiome and inflammatory bowel disease. J Allergy Clin Immunol. 2020;145:16-27. https://doi.org/10.1016/j.jaci.2019.11.003.
[6] Cao R, et al. Naringin exhibited therapeutic effects against DSS-induced mice ulcerative colitis in intestinal barrier-dependent manner. Molecules. 2021. https://doi.org/10.3390/molecules26216604.
[7] Shen Q, Huang Z, Yao J, Jin Y. Extracellular vesicles-mediated interaction within intestinal microenvironment in inflammatory bowel disease. J Adv Res. 2022;37:221-33. https://doi.org/10.1016/j.jare.2021.07.002.
[8] Schirmer M, et al. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell. 2016;167:1125-1136.e1128. https://doi.org/10.1016/j.cell.2016.10.020.
[9] Franzosa EA, et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol. 2019;4:293-305. https://doi.org/10.1038/s41564-018-0306-4.
[10] Moon J, Choi SH, Yoon CH, Kim MK. Gut dysbiosis is prevailing in Sjögren’s syndrome and is related to dry eye severity. PLoS ONE. 2020;15:e0229029. https://doi.org/10.1371/journal.pone.0229029.
[11] Huang R, et al. Correction: protective effect and mechanism insight of purified Antarctic krill phospholipids against mice ulcerative colitis combined with bioinformatics. Nat Prod Bioprospect. 2023;13:14. https://doi.org/10.1007/s13659-023-00379-y.
[12] Wan Y, et al. Effects of dietary fat on gut microbiota and faecal metabolites, and their relationship with cardiometabolic risk factors: a 6-month randomised controlled-feeding trial. Gut. 2019;68:1417-29. https://doi.org/10.1136/gutjnl-2018-317609.
[13] Ma WW, et al. The role of intestinal microbiota and metabolites in intestinal inflammation. Microbiol Res. 2024;288:127838. https://doi.org/10.1016/j.micres.2024.127838.
[14] Palmnäs-Bédard MSA, et al. The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs. Am J Clin Nutr. 2022;116:862-74. https://doi.org/10.1093/ajcn/nqac217.
[15] Zheng S, Xue T, Wang B, Guo H, Liu Q. Chinese medicine in the treatment of ulcerative colitis: the mechanisms of signaling pathway regulations. Am J Chin Med. 2022;50:1781-98. https://doi.org/10.1142/s0192415x22500756.
[16] Lu Z, et al. Naringin attenuates inflammatory injury to the bovine endometrium by regulating the endoplasmic reticulum stress-PI3K/AKT-autophagy axis. Front Pharmacol. 2024;15:1424511. https://doi.org/10.3389/fphar.2024.1424511.
[17] Yang S, et al. Osthole: an up-to-date review of its anticancer potential and mechanisms of action. Front Pharmacol. 2022;13:945627. https://doi.org/10.3389/fphar.2022.945627.
[18] Lin H, You Q, Wei X, Chen Z, Wang X. Osthole, a coumarin from Cnidium monnieri: a review on its pharmacology, pharmacokinetics, safety, and innovative drug delivery platforms. Am J Chin Med. 2024;52:1397-425. https://doi.org/10.1142/s0192415x24500678.
[19] Kordulewska NK, Topa J, Rozmus D, Jarmołowska B. Effects of osthole on inflammatory gene expression and cytokine secretion in histamine-induced inflammation in the Caco-2 cell line. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms222413634.
[20] Wei Y, et al. Based on network pharmacology to explore the potential bioactive compounds and mechanisms of Zuojin pill for the treatment of ulcerative colitis. Evid Based Complement Alternat Med. 2021;2021:7567025. https://doi.org/10.1155/2021/7567025.
[21] Ma J, et al. Modified Gegen Qinlian decoction ameliorates DSS-induced chronic colitis in mice by restoring the intestinal mucus barrier and inhibiting the activation of γδT17 cells. Phytomedicine. 2023;111:154660. https://doi.org/10.1016/j.phymed.2023.154660.
[22] Zhang S, et al. Effects of four food hydrocolloids on colitis and their regulatory effect on gut microbiota. Carbohydr Polym. 2024;323:121368. https://doi.org/10.1016/j.carbpol.2023.121368.
[23] Kuo WT, et al. Inflammation-induced occludin downregulation limits epithelial apoptosis by suppressing caspase-3 expression. Gastroenterology. 2019;157:1323-37. https://doi.org/10.1053/j.gastro.2019.07.058.
[24] Zhu S, et al. Gelatin versus its two major degradation products, prolyl-hydroxyproline and glycine, as supportive therapy in experimental colitis in mice. Food Sci Nutr. 2018;6:1023-31. https://doi.org/10.1002/fsn3.639.
[25] Ye Z, et al. Epithelial mitochondrial fission-mediated PANoptosis is crucial for ulcerative colitis and its inhibition by saquinavir through Drp1. Pharmacol Res. 2024;210:107538. https://doi.org/10.1016/j.phrs.2024.107538.
[26] Zhao Y, et al. FGL2 improves experimental colitis related to gut microbiota structure and bile acid metabolism by regulating macrophage autophagy and apoptosis. Heliyon. 2024;10:e34349. https://doi.org/10.1016/j.heliyon.2024.e34349.
[27] Wu J, et al. Rhein modulates host purine metabolism in intestine through gut microbiota and ameliorates experimental colitis. Theranostics. 2020;10:10665-79. https://doi.org/10.7150/thno.43528.
[28] Moffett JR, et al. Quinolinate as a marker for kynurenine metabolite formation and the unresolved question of NAD(+) synthesis during inflammation and infection. Front Immunol. 2020;11:31. https://doi.org/10.3389/fimmu.2020.00031.
[29] Mastropietro G, Tiscornia I, Perelmuter K, Astrada S, Bollati-Fogolín M. HT-29 and Caco-2 reporter cell lines for functional studies of nuclear factor kappa B activation. Mediat Inflamm. 2015;2015:860534. https://doi.org/10.1155/2015/860534.
[30] Ismail EN, et al. Polyphenols mitigating inflammatory mechanisms in inflammatory bowel disease (IBD): focus on the NF-κB and JAK/STAT pathways. Inflammopharmacology. 2024. https://doi.org/10.1007/s10787-024-01607-8.
[31] Wu Q, et al. JNK signaling in cancer cell survival. Med Res Rev. 2019;39:2082-104. https://doi.org/10.1002/med.21574.
[32] Gros B, Kaplan GG. Ulcerative colitis in adults: a review. JAMA. 2023;330:951-65. https://doi.org/10.1001/jama.2023.15389.
[33] Tan C, et al. Diosmin alleviates colitis by inhibiting PANoptosis of intestinal epithelial cells and regulating gut microbiota and metabolites. Phytomedicine. 2025;141:156671. https://doi.org/10.1016/j.phymed.2025.156671.
[34] Zheng BX, et al. Geniposide via enema alleviates colitis by modulating intestinal flora and bile acid metabolites, inhibiting S100A8/S100A9/NF-κB, and promoting TGR5 inhibition of NLRP3 inflammasome. Phytomedicine. 2025;142:156791. https://doi.org/10.1016/j.phymed.2025.156791.
[35] Sun M, Sun M, Zhang J. Osthole: an overview of its sources, biological activities, and modification development. Med Chem Res. 2021;30:1767-94. https://doi.org/10.1007/s00044-021-02775-w.
[36] Li R, et al. Integrated 16S rRNA gene sequencing and metabolomics analysis to investigate the important role of osthole on gut microbiota and serum metabolites in neuropathic pain mice. Front Physiol. 2022;13:813626. https://doi.org/10.3389/fphys.2022.813626.
[37] Huang J, Liu L, Chen C, Gao Y. PCOS without hyperandrogenism is associated with higher plasma trimethylamine N-oxide levels. BMC Endocr Disord. 2020;20:3. https://doi.org/10.1186/s12902-019-0486-9.
[38] Tang X, et al. Butyric acid increases the therapeutic effect of EHLJ7 on ulcerative colitis by inhibiting JAK2/STAT3/SOCS1 signaling pathway. Front Pharmacol. 2019;10:1553. https://doi.org/10.3389/fphar.2019.01553.
[39] Walujkar SA, et al. Molecular profiling of mucosal tissue associated microbiota in patients manifesting acute exacerbations and remission stage of ulcerative colitis. World J Microbiol Biotechnol. 2018;34:76. https://doi.org/10.1007/s11274-018-2449-0.
[40] Tsai YC et al. Alternations of the gut microbiota and the Firmicutes/Bacteroidetes ratio after biologic treatment in inflammatory bowel disease. J Microbiol Immunol Infect. 2024. https://doi.org/10.1016/j.jmii.2024.09.006
[41] Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146:1489-99. https://doi.org/10.1053/j.gastro.2014.02.009.
[42] Fu Y, Lyu J, Wang S. The role of intestinal microbes on intestinal barrier function and host immunity from a metabolite perspective. Front Immunol. 2023;14:1277102. https://doi.org/10.3389/fimmu.2023.1277102.
[43] Hu Y, Chen Z, Xu C, Kan S, Chen D. Disturbances of the gut microbiota and microbiota-derived metabolites in inflammatory bowel disease. Nutrients. 2022. https://doi.org/10.3390/nu14235140.
[44] Roager HM, Licht TR. Microbial tryptophan catabolites in health and disease. Nat Commun. 2018;9:3294. https://doi.org/10.1038/s41467-018-05470-4.
[45] Moffett JR, Blinder KL, Venkateshan CN, Namboodiri MA. Differential effects of kynurenine and tryptophan treatment on quinolinate immunoreactivity in rat lymphoid and non-lymphoid organs. Cell Tissue Res. 1998;293:525-34. https://doi.org/10.1007/s004410051145.
[46] Grant RS, Passey R, Matanovic G, Smythe G, Kapoor V. Evidence for increased de novo synthesis of NAD in immune-activated RAW264.7 macrophages: a self-protective mechanism? Arch Biochem Biophys. 1999;372:1-7. https://doi.org/10.1006/abbi.1999.1381.
[47] Grant RS. Indoleamine 2,3-dioxygenase activity increases NAD+ production in IFN-γ-stimulated human primary mononuclear cells. Int J Tryptophan Res. 2018;11:1178646917751636. https://doi.org/10.1177/1178646917751636.
[48] Lovelace MD, et al. Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases. Neuropharmacology. 2017;112:373-88. https://doi.org/10.1016/j.neuropharm.2016.03.024.
[49] Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9:537-49. https://doi.org/10.1038/nrc2694.
[50] Wei YY, et al. Shaoyao decoction attenuates DSS-induced ulcerative colitis, macrophage and NLRP3 inflammasome activation through the MKP1/NF-κB pathway. Phytomedicine. 2021;92:153743. https://doi.org/10.1016/j.phymed.2021.153743.
[51] Zeke A, Misheva M, Reményi A, Bogoyevitch MA. JNK signaling: regulation and functions based on complex protein-protein partnerships. Microbiol Mol Biol Rev. 2016;80:793-835. https://doi.org/10.1128/mmbr.00043-14.
[52] Pan HT, Xi ZQ, Wei XQ, Wang K. A network pharmacology approach to predict potential targets and mechanisms of “Ramulus Cinnamomi (cassiae) - Paeonia lactiflora” herb pair in the treatment of chronic pain with comorbid anxiety and depression. Ann Med. 2022;54:413-25. https://doi.org/10.1080/07853890.2022.2031268.